Cartalax
Also known as Cartilage bioregulator peptide
A bioregulator peptide product discussed in cartilage, joint, and connective-tissue aging contexts, with evidence best treated as preliminary and formulation-dependent.
Overview
Cartalax is a peptide-adjacent bioregulator product marketed around cartilage and joint tissue. Unlike single-sequence peptides, product identity and composition may vary by source.
The Science
The research premise is support of cartilage-cell function and extracellular-matrix maintenance.
- Cartilage matrix biology - collagen, proteoglycans, and chondrocyte function.
- Joint aging - tissue maintenance and inflammatory wear patterns.
- Bioregulator uncertainty - product definitions need to be checked carefully.
Evidence Snapshot
Cartalax does not have the evidence depth of established osteoarthritis medicines or well-characterized single peptides. It belongs in the directory as a research profile, not a validated joint therapy.
Related
More in Healing & Recovery
ARA-290
InvestigationalHealing & Recovery
An erythropoietin-derived peptide studied for tissue-protective and anti-inflammatory signaling without the red-blood-cell stimulation associated with EPO.
Botulinum Toxin
FDA-approvedHealing & Recovery
Not a peptideProtein toxin
A bacterial neurotoxin protein used clinically in tightly controlled doses for neuromuscular, migraine, autonomic, and cosmetic indications; it is not a peptide supplement.
BPC-157
Research compoundHealing & Recovery
A stable 15-amino-acid peptide fragment derived from a protein in human gastric juice, widely studied in preclinical models for tissue protection and repair across gut, tendon, muscle, and vascular tissue.